Impressive presentation! at least it tells us what's happening with the LOXL2 deal.
As to the Gilead's LOXL2 failure, it doesn't necessarily cast a doubt for the whole business, one horse's fall can't stop the race, as long as Pharmaxis's date is good.
Ann: Pharmaxis Science Update - Anti-Fibrotic Pipeline, page-2
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
-0.003(6.67%) |
Mkt cap ! $57.67M | |||
| Open | High | Low | Value | Volume |
| 4.4¢ | 4.5¢ | 4.2¢ | $37.11K | 834.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 244513 | 4.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 220000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| SNT (ASX) Chart |